ETTXのチャート
ETTXの企業情報
| symbol | ETTx |
|---|---|
| 会社名 | Entasis Therapeutics Holdings Inc （エンタシス・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | ― 医療関連（Health Care） |
| 概要 | 事業概要 -- エンタシス・セラピュ―ティクスは米国のバイオ医薬品事業持株会社。子会社を通じ、多剤耐性グラム陰性菌感染症の治療薬の新規発見、開発および商業化に焦点をあて事業を行う。主に多剤耐性アシネトバクタ―感染症、淋病、複雑性尿路感染症などの治療薬の臨床試験を手掛ける。本社所在地はマサチュ―セッツ州ウォルサム。 Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). |
| 本社所在地 | 35 Gatehouse Drive Waltham MA 02451 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | 42064 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | 34人 |
| url | www.entasistx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ettx |
| adr_tso | ― |
| EBITDA | EBITDA ー |
| 終値（lastsale） | 8.31 |
| 時価総額（marketcap） | 0 |
| 時価総額 | 時価総額 ― |
| 売上高 | 売上高 -- |
| 企業価値(EV) | 企業価値(EV) ー |
| 当期純利益 | 当期純利益 -- |
| 決算概要 | 決算概要 -- |
ETTXのテクニカル分析
ETTXのニュース
La Jolla Pharmaceutical (LJPC) Stock Skyrockets on Innoviva Acquisition News 2022/07/11 15:15:14 InvestorPlace
In a development that’s garnering attention in the healthcare sector, La Jolla Pharmaceutical (NASDAQ: LJPC ) has reportedly consented to be acquired by Innovia (NASDAQ: INVA ). As a result, LJPC stock soon likely won’t be listed on the Nasdaq exchange, or any public market for that matter. It’s not hard to figure out why Innovia would want to own La Jolla’s assets. La Jolla already has multiple regulatory wins under its belt. In 2017, the Food and Drug Administration (FDA) approved GIAPREZA , La Jolla’s lead product, to increase blood pressure in adults with septic or other distributive shock. Also, in 2018 the FDA approved La Jolla subsidiary Tetraphase’s XERAVA to treat complicated intra-abdominal infections in patients 18 years of age and older. Thus, acquiring La Jolla Pharmaceutical will help Innovia strengthen its infectious-diseases portfolio. Apparently, Innovia was already moving in this direction through its recent purchase of Entasis Therapeutics, which develops novel antibacterial products.
Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc. 2022/07/08 12:35:00 Wallstreet:Online
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”) at a price of $2.20 per share, net to the seller in cash, without interest and less required withholding taxes, expired at 5:00 p.m. New York City time on Thursday, July 7, 2022.
La Jolla Pharmaceutical (LJPC) Stock Skyrockets on Innoviva Acquisition News 2022/07/11 15:15:14 InvestorPlace
In a development that’s garnering attention in the healthcare sector, La Jolla Pharmaceutical (NASDAQ: LJPC ) has reportedly consented to be acquired by Innovia (NASDAQ: INVA ). As a result, LJPC stock soon likely won’t be listed on the Nasdaq exchange, or any public market for that matter. It’s not hard to figure out why Innovia would want to own La Jolla’s assets. La Jolla already has multiple regulatory wins under its belt. In 2017, the Food and Drug Administration (FDA) approved GIAPREZA , La Jolla’s lead product, to increase blood pressure in adults with septic or other distributive shock. Also, in 2018 the FDA approved La Jolla subsidiary Tetraphase’s XERAVA to treat complicated intra-abdominal infections in patients 18 years of age and older. Thus, acquiring La Jolla Pharmaceutical will help Innovia strengthen its infectious-diseases portfolio. Apparently, Innovia was already moving in this direction through its recent purchase of Entasis Therapeutics, which develops novel antibacterial products.
Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc. 2022/07/08 12:35:00 Wallstreet:Online
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”) at a price of $2.20 per share, net to the seller in cash, without interest and less required withholding taxes, expired at 5:00 p.m. New York City time on Thursday, July 7, 2022.
ENTASIS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of ETTX and Encourages Investors to Contact the Firm 2022/05/24 20:04:00 GlobeNewswire
NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Innoviva, Inc. (NASDAQ: INVA).
Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share 2022/05/23 14:04:44 Benzinga
Innoviva Inc (NASDAQ: INVA ) has agreed to acquire Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) at $2.20 per share in cash. Innoviva currently owns approximately 60% of the outstanding shares of Entasis common stock. The acquisition consideration values Entasis'' equity at $113 million on a fully diluted basis. "This acquisition will build upon our overall strategy to acquire … Full story available on Benzinga.com
GeoVax, Entasis top healthcare gainers, while Nymox, Evoke Pharma lead losers'' pack 2022/05/23 14:01:40 Seeking Alpha
GeoVax Labs GOVX +39%. Entasis Therapeutics ETTX +21%. Nymox Pharmaceutical NYMX -67%. Evoke Pharma EVOK -21%.
La Jolla Pharmaceutical (LJPC) Stock Skyrockets on Innoviva Acquisition News 2022/07/11 15:15:14 InvestorPlace
In a development that’s garnering attention in the healthcare sector, La Jolla Pharmaceutical (NASDAQ: LJPC ) has reportedly consented to be acquired by Innovia (NASDAQ: INVA ). As a result, LJPC stock soon likely won’t be listed on the Nasdaq exchange, or any public market for that matter. It’s not hard to figure out why Innovia would want to own La Jolla’s assets. La Jolla already has multiple regulatory wins under its belt. In 2017, the Food and Drug Administration (FDA) approved GIAPREZA , La Jolla’s lead product, to increase blood pressure in adults with septic or other distributive shock. Also, in 2018 the FDA approved La Jolla subsidiary Tetraphase’s XERAVA to treat complicated intra-abdominal infections in patients 18 years of age and older. Thus, acquiring La Jolla Pharmaceutical will help Innovia strengthen its infectious-diseases portfolio. Apparently, Innovia was already moving in this direction through its recent purchase of Entasis Therapeutics, which develops novel antibacterial products.
Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc. 2022/07/08 12:35:00 Wallstreet:Online
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”) at a price of $2.20 per share, net to the seller in cash, without interest and less required withholding taxes, expired at 5:00 p.m. New York City time on Thursday, July 7, 2022.
ENTASIS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of ETTX and Encourages Investors to Contact the Firm 2022/05/24 20:04:00 GlobeNewswire
NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Innoviva, Inc. (NASDAQ: INVA).
Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share 2022/05/23 14:04:44 Benzinga
Innoviva Inc (NASDAQ: INVA ) has agreed to acquire Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) at $2.20 per share in cash. Innoviva currently owns approximately 60% of the outstanding shares of Entasis common stock. The acquisition consideration values Entasis'' equity at $113 million on a fully diluted basis. "This acquisition will build upon our overall strategy to acquire … Full story available on Benzinga.com